Taito Esaki

Sign up to set email alerts
|
45Publications
3,345Citation Statements Received
644Citation Statements Given
How they've been cited
4,881
158
3,155
32
How they cite others
906
60
577
7
Publications
Order By: Most citations

Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial

Hironaka
1
,
Ueda
2
,
Yasui
3
et al. 2013
JCO
438
23
285
4
View full textAdd to dashboardCite
show abstract

TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial

Yoshino
1
,
Mizunuma
2
,
Yamazaki
3
et al. 2012
The Lancet Oncology
277
20
249
4
View full textAdd to dashboardCite

Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)

Muro
1
,
Boku
2
,
Shimada
3
et al. 2010
The Lancet Oncology
198
2
165
2
View full textAdd to dashboardCite

Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies

Nakamura
1
,
Taniguchi
2
,
Ikeda
3
et al. 2020
Nat Med
225
5
160
0
View full textAdd to dashboardCite

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

Yamazaki
1
,
Nagase2,
Tamagawa
3
et al. 2016
Annals of Oncology
195
10
138
4
View full textAdd to dashboardCite
show abstract

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Fuchs
1
,
Shitara
2
,
Bartolomeo
3
et al. 2019
The Lancet Oncology
195
6
124
0
2
View full textAdd to dashboardCite

Development of a shear-flow test apparatus and determination of coupled properties for a single rock joint

Esaki
1
,
Du
2
,
Mitani
3
et al. 1999
International Journal of Rock Mechanics and Mining Sciences
258
9
117
0
View full textAdd to dashboardCite

Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

Siena
1
,
Bartolomeo
2
,
Raghav
3
et al. 2021
The Lancet Oncology
245
0
112
1
View full textAdd to dashboardCite
scite logo

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

334 Leonard St

Brooklyn, NY 11211

Product
Browser ExtensionAssistant by sciteCitation Statement SearchReference CheckVisualizationsDashboardsExplore JournalsExplore OrganizationsExplore FundersEmbedding BadgeEmbedding Citation SearchPricing
Resources
BlogHelp & FAQAccessibility StatementAPI TermsFor Universities & GovernmentsFor ResearchersFor PublishersFor Corporate, Pharma & EnterpriseAuthor MarketingBecome an AffiliateGet an organization trial or quotescite Data & Services
About
News & PressCareersRead our PaperCoverage

BlogTerms and ConditionsAPI TermsPrivacy PolicyContactCookie PreferencesDo Not Sell or Share My Personal Information

Copyright © 2024 scite LLC. All rights reserved.

Made with 💙 for researchers

Part of the Research Solutions Family.